287 related articles for article (PubMed ID: 30100552)
1. Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort.
Wijburg MT; Warnke C; Barkhof F; Uitdehaag BMJ; Killestein J; Wattjes MP
J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):44-46. PubMed ID: 30100552
[TBL] [Abstract][Full Text] [Related]
2. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
[TBL] [Abstract][Full Text] [Related]
3. Application of "Mentzer's PML case definition" to natalizumab-treated patients in the setting of strict MRI-based pharmacovigilance.
Wijburg MT; Warnke C; Killestein J; Wattjes MP
J Neurol; 2020 Sep; 267(9):2599-2602. PubMed ID: 32385682
[TBL] [Abstract][Full Text] [Related]
4. Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
Hodel J; Darchis C; Outteryck O; Verclytte S; Deramecourt V; Lacour A; Zins M; Pruvo JP; Vermersch P; Leclerc X
Neurology; 2016 Apr; 86(16):1516-23. PubMed ID: 27009257
[TBL] [Abstract][Full Text] [Related]
5. Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question.
De Mercanti SF; Gned D; Matta M; Iudicello M; Franchin E; Clerico M
J Investig Med High Impact Case Rep; 2020; 8():2324709620939802. PubMed ID: 32646245
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS.
Wattjes MP; Wijburg MT; van Eijk J; Frequin S; Uitdehaag BMJ; Barkhof F; Warnke C; Killestein J;
J Neurol Neurosurg Psychiatry; 2018 May; 89(5):535-541. PubMed ID: 29142146
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry.
Prosperini L; de Rossi N; Scarpazza C; Moiola L; Cosottini M; Gerevini S; Capra R;
PLoS One; 2016; 11(12):e0168376. PubMed ID: 27997580
[TBL] [Abstract][Full Text] [Related]
8. Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?
Scarpazza C; Prosperini L; Mancinelli CR; De Rossi N; Lugaresi A; Capobianco M; Moiola L; Naldi P; Imberti L; Gerevini S; Capra R
J Neurol Sci; 2017 Jul; 378():233-237. PubMed ID: 28566170
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.
Warnke C; von Geldern G; Markwerth P; Dehmel T; Hoepner R; Gold R; Pawlita M; Kümpfel T; Mäurer M; Stangel M; Wegner F; Hohlfeld R; Straeten V; Limmroth V; Weber T; Hermsen D; Kleinschnitz C; Hartung HP; Wattjes MP; Svenningson A; Major E; Olsson T; Kieseier BC; Adams O
Ann Neurol; 2014 Dec; 76(6):792-801. PubMed ID: 24729444
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Richert ND; Uitdehaag BM; Barkhof F; Killestein J
Mult Scler; 2016 Aug; 22(9):1174-83. PubMed ID: 26564995
[TBL] [Abstract][Full Text] [Related]
11. Asymptomatic Progressive Multifocal Leukoencephalopathy Associated with Natalizumab: Diagnostic Precision with MR Imaging.
Hodel J; Outteryck O; Dubron C; Dutouquet B; Benadjaoud MA; Duhin E; Verclytte S; Zins M; Luciani A; Rahmouni A; Pruvo JP; Vermersch P; Leclerc X
Radiology; 2016 Mar; 278(3):863-72. PubMed ID: 26436861
[TBL] [Abstract][Full Text] [Related]
12. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?
Wattjes MP; Vennegoor A; Mostert J; van Oosten BW; Barkhof F; Killestein J
J Neurol; 2014 Jun; 261(6):1139-43. PubMed ID: 24705790
[TBL] [Abstract][Full Text] [Related]
14. Quantitative electroencephalography supports diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.
Classen G; Classen C; Bernasconi C; Brandt C; Gold R; Chan A; Hoepner R
J Neurovirol; 2019 Feb; 25(1):133-136. PubMed ID: 30414049
[TBL] [Abstract][Full Text] [Related]
15. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.
Dong-Si T; Gheuens S; Gangadharan A; Wenten M; Philip J; McIninch J; Datta S; Richert N; Bozic C; Bloomgren G; Richman S; Weber T; Clifford DB
J Neurovirol; 2015 Dec; 21(6):637-44. PubMed ID: 25771865
[TBL] [Abstract][Full Text] [Related]
16. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
Clifford DB; De Luca A; Simpson DM; Arendt G; Giovannoni G; Nath A
Lancet Neurol; 2010 Apr; 9(4):438-46. PubMed ID: 20298967
[TBL] [Abstract][Full Text] [Related]
17. Treatment of natalizumab-associated PML with filgrastim.
Stefoski D; Balabanov R; Waheed R; Ko M; Koralnik IJ; Sierra Morales F
Ann Clin Transl Neurol; 2019 May; 6(5):923-931. PubMed ID: 31139690
[TBL] [Abstract][Full Text] [Related]
18. Comparison of qPCR with ddPCR for the Quantification of JC Polyomavirus in CSF from Patients with Progressive Multifocal Leukoencephalopathy.
Ngouth N; Monaco MC; Walker L; Corey S; Ikpeama I; Fahle G; Cortese I; Das S; Jacobson S
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746716
[TBL] [Abstract][Full Text] [Related]
19. Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy.
Warnke C; Wijburg MT; Hartung HP; Killestein J; Adams O; Wattjes MP
J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1092-1094. PubMed ID: 28490505
[No Abstract] [Full Text] [Related]
20. Course of neuropsychological impairment during natalizumab-associated progressive multifocal leukoencephalopathy.
Kinner M; Prehn C; Schneider R; Schroeder C; Kolb E; Gold R; Hoepner R; Chan A
Eur J Neurol; 2021 Mar; 28(3):921-927. PubMed ID: 33085811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
